Pure Global AI
NCT06095284Enrolling by invitation

Prescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic

Prescribing Trends and Associated Outcomes of Antiepileptic Drugs and Other Psychoactive Medications in US Nursing Homes Surrounding the COVID-19 Pandemic
Virginia Commonwealth UniversityClinicalTrials.govother
Verified
Study focus
Disease/Condition
Dementia
Drug/Device/Intervention
Pre-Extraction Phase
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Virginia Commonwealth University
Location
Richmond, United States of America
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2022
End date
Jun 30, 2027
Enrollment
22500000 participants
Primary outcome

Quarterly rate of use and mean dose of AEDs in US nursing homes

Summary

Since the National Partnership to Improve Dementia Care debuted in 2012, almost all
 long-stay psychoactive prescribing has been graded by CMS, which has correlated to decreased
 use. However, some national data suggest that while these psychoactive medications are being
 used less, prescriptions of mood-stabilizing antiepileptic drugs (AEDs) have increased.
 Unlike all other psychoactive medications, AEDs prescribed in nursing homes are not
 mandatorily reported to CMS or graded in a quality-measure.

ICD-10 classifications
Unspecified dementiaAlzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecifiedDementia in other diseases classified elsewhere
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06095284
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06095284 through Pure Global AI's free database. This phase not specified trial is sponsored by Virginia Commonwealth University and is currently Enrolling by invitation. The study focuses on Dementia. Target enrollment is 22500000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.